A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

New England Journal of Medicine

Volumn 335, Issue 6, 1996, Pages 384-391

  Pierce, Mark ^a   Crampton, Sheri ^b   Henry, David ^b   Heifets, Leonid ^c   Lamarca, Anthony ^d   Montecalvo, Marisa ^e   Wormser, Gary P ^f   Jablonowski, Helmut ^g   Jemsek, Joseph ^h   Cynamon, Michael ⁱ   Yangco, Bienvenido G ^j   Notario, Gerard ^b   Craft, J Carl ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d Therafirst Medical Center   (United States)

^e WESTCHESTER MEDICAL CENTER   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h Nalle Clinic   (United States)

ⁱ SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^j INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; TASTE DISORDER;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 9344235425     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608083350603     Document Type: Article

References (24)

1. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324: 1332-8.
2. 3: Multicenter AIDS Cohort Study. J Infect Dis 1994;170:1284-7.
3. Havlik JA Jr, Horsburgh CR Jr, Metchock B, Williams PP, Fann SA, Thompson SE III. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992;165: 577-80.
4. Horsburgh CR Jr, Havlik JA, Ellis DA, et al. Survival of patients with acquired immunodeficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557-9.
5. Chin DP, Reingold AL, Stone EN, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994;170:578-84.
6. Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989;33:1531-4.
7. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled clinical trial. Am Rev Respir Dis 1991;144:564-9.
8. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121:905-11.
9. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1993;42(RR-9):14-20.
10. COSTART: coding symbols for thesaurus of adverse reaction terms. 2nd ed. Rockville, Md.: Food and Drug Administration, 1989.
11. Sanchez T, Vanderkolk J, Seay S, Heifets L. Quantitation of mycobacteria in blood specimens from patients with AIDS. Tuber Lung Dis 1994; 75:386-90.
12. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992;145:856-8.
13. SAS user's guide: statistics, version 6 ed. Cary, N.C.: SAS Institute, 1991.
14. Lakatos EL. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials 1986;7: 189-99.
15. Wu M, Fisher M, DeMets D. Sample sizes for long-term medical trials with time-dependent dropout and event rates. Control Clin Trials 1980;1: 111-23.
16. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
17. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
18. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
19. Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995;9:1337-42.
20. Denis M, Ghadirian E. Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens. Clin Exp Immunol 1994;97:76-82.
21. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T, Zidovudine Epidemiology Study Group. Incidence and natural history of Mycobncterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992;146:285-9.
22. Hanson DL, Horsburgh CR Jr, Fann SA, Havlik JA, Thompson SE III. Survival prognosis of HIV-infected patients. J Acquir Immune Defic Syndr 1993;6:624-9.
23. Meissner G, Anz W. Sources of Mycobacterium avium complex infection resulting in human disease. Am Rev Respir Dis 1977;116:1057-64.
24. Disseminated infection with Mycobacterium avium complex. In: USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44(RR-8):11-2.